Inflammatory bowel disease (IBD), encompassing Crohn’s disease and ulcerative colitis (UC), is a key area of focus for Janssen. Since introducing the first tumor necrosis factor (TNF) inhibitor to the market in 1998 for the treatment of Crohn’s disease, we changed the IBD treatment paradigm and remain focused in this disease area.

Scientific studies over recent years have elucidated an increased understanding of the pathophysiology of IBD, in particular, increased knowledge of the mucosal immune system and its relationship to the microbiome. Therefore, the interplay between the gut and its environment is a strong focus of research at Janssen as we seek opportunities to prevent, intercept and ultimately, cure IBD.

Our unique clinical and research capabilities and expertise, combined with a track record of operational excellence and success, have fostered a robust, prioritized pipeline and strategy for the future. With the introduction of new alternative mechanism of action (MOA) biologics and oral treatments, and investment in predictive biomarkers, Janssen remains committed to developing differentiated treatments for both patients living with IBD and healthcare professionals.